Latest Factor XI Stories
Antisense Approach for Clotting Disorders WHIPPANY, N.J., May 4, 2015 /PRNewswire/ -- Bayer HealthCare (Bayer) has entered into an exclusive license agreement with Isis Pharmaceuticals,
--Bayer to develop ISIS-FXI Rx broadly for the prevention of thrombosis-- CARLSBAD, Calif., May 4, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
Seven-fold lower incidence of VTE in patients treated with ISIS-FXI Rx compared with enoxaparin CARLSBAD, Calif., Dec. 7, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
DEAL SOLIDIFIES LONG-TERM COMMITMENT TO CUSTOMERS, EMPLOYEES & COMMUNITY ORANGE, Calif., July 7, 2014 /PRNewswire/ -- FXI, the leading producer of innovative foam products, announced
Seven-fold lower incidence of VTEs in patients treated with ISIS-FXIRx compared to enoxaparin CARLSBAD, Calif., May 22, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
- A young chicken: also used as a pet name for children.